


*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**SINO BIOPHARMACEUTICAL LIMITED**  
**中國生物製藥有限公司**

*(Incorporated in the Cayman Islands with limited liability)*

*Website: [www.sinobiopharm.com](http://www.sinobiopharm.com)*

**(Stock code: 1177)**

**VOLUNTARY ANNOUNCEMENT**  
**ENTERING INTO LICENSE AND TRANSFER AGREEMENT**

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that Chia Tai-Tianqing Pharmaceutical Holdings Nanjing Shunxin Pharmaceutical Co., Ltd. (正大天晴藥業集團南京順欣製藥有限公司) (“**Chia Tai-Tianqing**”), a subsidiary of the Company, entered into the exclusive license and transfer agreement for the development and commercialisation rights in China and certain Asian regions of AP025 and AP026, novel biologics for the treatment of non-alcoholic steatohepatitis (NASH) and type II diabetes mellitus (T2DM) respectively, with Anyuan Pharmaceutical Technology (Shanghai) Co., Ltd. (安源醫藥科技(上海)有限公司) (“**Anyuan Pharmaceutical**”). Currently, AP025 is at Phase I clinical trials in China, while AP026 is at Phase I clinical trials overseas and is scheduled to file an IND (Investigational New Drug Application) in China in 2022.

The signing of the exclusive license and transfer agreement will enable the parties to leverage on the technologies and products developed by Anyuan Pharmaceutical’s own innovative CHO production cell line development platform, high affinity antibody creation platform, ultra-long-lasting protein design platform and PACE bispecific antibody technology platform to develop and manufacture high quality medicines for Chinese patients and leverage on Chia Tai-Tianqing’s strong process, clinical development and commercialisation capabilities as well as its market advantages in the fields of liver diseases and diabetes in China to speed up the progress of clinical trials and benefit Chinese patients. At the same time, this collaboration also lays a good foundation for both parties to further deepen their cooperation in the metabolism products of the Anyuan Pharmaceutical’s pipeline in the future.

## **ABOUT AP025**

AP025 is a human derived FGF21 fusion protein for the treatment of NASH, a more severe form of non-alcoholic fatty liver disease (NAFLD) that involves significant inflammation and is associated with liver necrosis, fibrosis and other pathological signs, for which there is currently no FDA (US Food and Drug Administration) approved treatment and for which there is a significant unmet clinical need. AP025 is the first product of its kind to conduct clinical trial in China, utilizing the unique linker platform technology of Anyuan Pharmaceutical to reduce the spatial block of Fc while protecting the biological activity of FGF21.

## **ABOUT AP026**

AP026 is a FGF21/GLP-1 bifunctional protein. Its fusion with the Fc-terminus by utilizing the unique linker platform technology of Anyuan Pharmaceutical can effectively increase the stability of the molecule in the blood. Based on the demonstrated good effect of GLP-1 metabolism and the strong potential of FGF21, this product is expected to be an important player in the metabolism field such as NASH and type II diabetes mellitus.

## **ABOUT ANYUAN PHARMACEUTICAL**

Anyuan Pharmaceutical is a biopharmaceutical company focused on new drug discovery and process development and optimization. It is dedicated to the development of internationally novel, original targeted macromolecules and complementary diagnostic reagents with First-in-class or Best-in-class potential, and develops products and core technologies in the areas of tumour immunology, metabolic diseases and autoimmune diseases.

By order of the Board  
**Sino Biopharmaceutical Limited**  
**Tse, Theresa Y Y**  
*Chairwoman*

Hong Kong, 25 April 2022

*As at the date of this announcement, the Board of the Company comprises nine executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Li Yi, Mr. Wang Shanchun, Mr. Tian Zhoushan and Ms. Li Mingqin, and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.*